Treatment of complicated henoch-schnlein purpura with mycophenolate mofetil: A retrospective case series report

Publication Type:
Journal Article
Citation:
International Journal of Rheumatology, 2010, 2010
Issue Date:
2010-12-01
Full metadata record
Files in This Item:
Filename Description Size
Thumbnail2009006784OK.pdf495.84 kB
Adobe PDF
Background. Henoch-Schnlein purpura (HSP) is the most common childhood vasculitis with an incidence of approximately 10 per 100 000 children. There is some evidence to support steroid therapy in the treatment of severe abdominal pain, severe nephritis, and central nervous system involvement. However, the routine use of corticosteroids is controversial. Frequent relapses, lack of response to steroid, steroid dependency, and steroid side effects may occur in some patients. Mycophenolate mofetil (MMF) gains increasing popularity in the treatment of autoimmune disorders, but hitherto, the available evidence to support the use of MMF in HSP is limited to some case study reports. Case Presentation. We report six children with HSP who failed to respond to systemic steroid therapy, whereas MMF successfully treated the manifestations of the disease. Conclusion. The manifestations of HSP disappeared mainly during the first week of treatment with MMF and all the patients were in a complete remission at the end and after discontinuation of the therapy. In our experience, MMF appeared to be safe and effective for the maintenance of remission in the HSP patients. Copyright © 2010 A. A. Nikibakhsh et al.
Please use this identifier to cite or link to this item: